NY-CORSEARCH
31.1.2020 13:02:09 CET | Business Wire | Press release
Corsearch, a trademark and brand protection solutions leader, is pleased to announce the acquisition of Pointer Brand Protection, a prominent provider of anti-counterfeiting and brand protection services. The acquisition further extends Corsearch’s fast-growing brand protection offering and provides a comprehensive new service for brand owners and legal professionals. For the first time, a consolidated suite of technologically advanced solutions will support the research, clearance, monitoring, investigative, and enforcement needs of the brand lifecycle.
From counterfeiting and piracy to gray trade and brand impersonation, estimates suggest that a staggering one in four online purchases involve brand infringement. With global eCommerce expected to reach 4.5 trillion U.S. dollars by 2021, the need for online brand protection to fight these threats has never been more urgent. It is an issue that is growing in tandem with total global trade, with some reports projecting that by 2022 counterfeiting and piracy could result in the loss of 4.2 trillion U.S. dollars and the endangerment of 5.4 million legitimate jobs.
A global problem needs global solutions, and the addition of Pointer Brand Protection into the Corsearch family aligns the technological capabilities and extensive networks of the entire group into a brand establishment and protection provider with unmatched coverage.
For many businesses, the digital environment has become so complex that establishing and protecting brands is too fragmented and time consuming to be manageable. To combat this effectively, brand owners and legal professionals require technological leadership and innovative solutions to implement a strong, proactive brand protection program. The Corsearch Brand Protection platform will provide an entirely new service offering which combines the very best teams, expertise, and technologies from both Pointer and from previous Corsearch acquisition, Yellow Brand Protection. In addition to Corsearch’s existing services, the new platform will provide brands with a full-service solution combining everything from trademark research and clearing to machine learning, automated marketplace enforcement, and end-to-end investigations. To fight infringements at their source, the new team will also include the largest China-based online brand protection department in the industry.
“Since 2008, Pointer has worked with hundreds of globally-renowned brands to protect them from infringement and abuse,” said Pointer CEO, Robert Stolk. “The industry is becoming more challenging every day and brands require technologies and services that can outpace that. Joining forces with Corsearch means securing the ability to innovate in a way that anticipates the needs of customers while also benefiting from Corsearch’s trusted industry presence.”
Corsearch’s CEO, Tobias Hartmann, commented, “We are thrilled to bring the brightest minds in online brand protection together and define the future of this industry. With this strategic acquisition Corsearch becomes the only provider to support the needs of IP and brand professionals throughout the trademark lifecycle.”
About Corsearch
Corsearch (www.corsearch.com ) is a leading provider of clearance and online brand protection solutions for trademark and brand professionals. With highly trained researchers, an expansive global content set, and customer-focused technology tools available through the Corsearch platform, Corsearch empowers its customers with powerful brand solutions in an increasingly complex business environment.
Founded in 1949 and headquartered in New York, Corsearch now has over 450 employees working across its 10 global offices. Corsearch has advised 43 of the world’s top 50 brands and has in excess of 5,000 clients around the world.
For more information please contact Stephen Stolfi, Chief Commercial Officer, or visit corsearch.com.
About Pointer
Pointer Brand Protection (https://pointerbrandprotection.com/ ) has been defending global brands from counterfeiting and brand abuse since 2008. With more than 120 employees working from offices in Amsterdam, Shanghai, New York, and London, Pointer is an industry leader in the fight against brand infringement. Pointer offers holistic and bespoke anti-counterfeiting solutions that include online-to-offline investigations, test purchasing services, dedicated brand protection analysts, and a proprietary software platform for the removal of infringements. Its mission is to clean the online marketplace in order to create safety for consumers, to increase the integrity of hard-working brands, and to reduce the negative societal impact of counterfeiting.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200131005016/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom